A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.

[1]  G. Scambia,et al.  Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials , 2010, Expert review of anticancer therapy.

[2]  S. Coughlin.  Surviving Cancer or Other Serious Illness: A Review of Individual and Community Resources , 2008, CA: a cancer journal for clinicians.

[3]  E. Jenison,et al.  Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery , 2007, Health and quality of life outcomes.

[4]  D. Cella,et al.  Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Movsas,et al.  Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. , 2006, International journal of radiation oncology, biology, physics.

[6]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[7]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[8]  B. Monk,et al.  Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Cashy,et al.  General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G) , 2005, Evaluation & the health professions.

[10]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[11]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[12]  A. Vickers.  Statistical considerations for use of composite health-related quality-of-life scores in randomized trials , 2004, Quality of Life Research.

[13]  R. Greil,et al.  Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors , 2004, Acta oncologica.

[14]  D. Cella,et al.  Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening , 2002, Quality of Life Research.

[15]  D. L. Fairclough,et al.  Functional Assessment of Cancer Therapy (FACT-G): Non-response to individual questions , 1996, Quality of Life Research.

[16]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[17]  D. Cella,et al.  Quality of life in patients receiving treatment for gynecologic malignancies: Special considerations for patient care , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[18]  C. Moinpour,et al.  Individual Differences in Quality-of-Life Treatment Response , 2002, Medical care.

[19]  David Cella,et al.  Resilience, reflection, and residual stress in ovarian cancer survivorship: A gynecologic oncology group study , 2002, Psycho-oncology.

[20]  D. Cella,et al.  Reliability and validity of the functional assessment of cancer therapy-ovarian. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Cella,et al.  An analysis of the impact of demographic, clinical, and social factors on health-related quality of life. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.